Drug patent plan gets mixed reviews

News Published: 23 February 2009 Drug patent plan gets mixed reviews Declan Butler  Nature volume 457, pages 1064–1065 (2009)Cite this article

90 Accesses

2 Citations

Metrics details

GlaxoSmithKline's bid to tackle neglected diseases receives a muted response from the rest of the industry.

Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution

Access options Access through your institution Additional access options: Log in Learn about institutional subscriptions Read our FAQs Contact customer support AuthorsDeclan ButlerView

author publications You can also search for this author inPubMed Google Scholar

Additional reporting by Natasha Gilbert

Outlook: Neglected Diseases

Supplement: A World of Science in the Developing World

Commentary: New uses for old drugs

Commentary: Neglected tests for neglected patients

Commentary: Experiments in social responsibility

Special: Malaria killer blow

MSF Campaign for Access to Essential Medicines

MSF on patent pools

Drugs for Neglected Diseases Initiative

GSK Access to Medicines site

Institute for OneWorld Health

UNITAID

Knowledge Ecology International

UN Least Developed Countries

Rights and permissions Reprints and permissions

About this articleCite this article Butler, D. Drug patent plan gets mixed reviews. Nature 457, 1064–1065 (2009). https://doi.org/10.1038/4571064a

Download citation

Published: 23 February 2009

Issue Date: 26 February 2009

DOI: https://doi.org/10.1038/4571064a

Share this article Anyone you share the following link with will be able to read this content:

Get shareable link Sorry, a shareable link is not currently available for this article.

Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative

This article is cited by Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery Michael R. BarnesLee HarlandCory R. Brouwer Nature Reviews Drug Discovery

(2009)